Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-15
Target enrollment:
Participant gender:
Summary
This phase II trial examines letrozole in patients with hormone receptor positive, HER2
negative breast cancer that can be removed by surgery (operable). Letrozole is in a class of
medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of
estrogen produced by the body. This can slow or stop the growth of some types of breast
cancer cells that need estrogen to grow.